fbpx Skip to main content

Member's Profile

OBI Pharma USA, Inc.

6020 Cornerstone Ct W Ste 200
San Diego,   California
United States
Membership Info
Membership Type: Industry
Membership Since: 2015
Need to make an update to your Member Profile or have a question? Contact us here: [email protected]
About OBI Pharma USA, Inc.
Biotech Company
OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H and SSEA-4), AKR1C3, and other promising targets.

The company’s novel first-in-class immuno-oncology therapeutic portfolio is targeted against Globo H: Adagloxad Simolenin (formerly OBI-822) and OBI 833 (vaccines), OBI-888 (mAb) and OBI-999 (ADC) and SSEA-4: OBI 866 (vaccine); OBI-898 (mAb) and OBI-998 (ADC). The company’s novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1c3 (AKR1C3) enzyme.
Related News
No related news posted by this Member